Antibody Name/Symbol |
Antibody Description |
Clones/Alternative Names |
Chapters |
κ light chain |
kappa light chain |
KAPPA |
Evaluation of Transplant Nephrectomy |
λ light chain |
lambda light chain |
LAMBDA |
Evaluation of Transplant Nephrectomy |
A1AT |
alpha 1 antitrypsin |
α1-antitrypsin |
Pathologic Classification of Lung Allograft Diseases |
Adenovirus |
|
|
Adenovirus, Intestine; Adenovirus, Kidney; Adenovirus, Liver Evaluation of Transplant Nephrectomy; Herpes Simplex Virus |
AE1/AE3 |
mixture of 2 anticytokeratin clones that detect a variety of both high-and lowmolecular weight cytokeratins |
Malakoplakia |
APC |
adenomatous polyposis coli protein |
|
|
Bcl-2 |
B-cell lymphoma 2; suppresses apoptosis in a variety of cell systems |
ONCL2, BCL2/100/D5, 124, 124.3 |
Epstein-Barr Virus, Liver |
Bcl-6 |
B-cell CLL/lymphoma 6 |
LN22, GI191E/A8, N-3, PG-B6P, P1F6, 3FR-1 |
Epstein-Barr Virus, Liver; Post-Transplant Lymphoproliferative Disorder |
Blood group antigens |
|
BGI |
Acute Antibody-Mediated Rejection, Intestine; Apheresis and Transplantation |
C4d |
degradation product of the activated complement factor 4, regarded as an indirect sign of antibody-mediated alloreactivity |
|
Accommodation; Acute Allograft Ischemia; Acute Antibody-Mediated Rejection, Intestine; Acute Antibody-Mediated Rejection, Kidney; Acute Cellular Rejection, Intestine; Acute Cellular Rejection, Kidney; Acute Cellular Rejection, Pancreas; Acute Pyelonephritis; Acute Rejection; Anti-GBM Disease in Alport Syndrome; Antibody-Mediated Rejection, Heart; Antibody-Mediated Rejection, Liver; Antibody-Mediated Rejection, Lung; Antibody-Mediated Rejection, Pancreas; Bacterial and Fungal Infections; Bile Duct Stricture, Leak, Sludge, Biloma; Calcineurin Inhibitor Toxicity; Chronic Allograft Rejection/Graft Sclerosis; Chronic Antibody-Mediated Rejection; Chronic Rejection; Chronic T-Cell-Mediated Rejection; Clinical Considerations in Pancreas Transplant Evaluation; Colon Rejection; Cytomegalovirus Nephritis; De Novo Focal Segmental Glomerulosclerosis; De Novo Membranous Glomerulonephritis; Diseases That Recur in Allografts; Engraftment Syndrome; Evaluation of Failed Liver Allograft; Evaluation of the Allograft Kidney; Evaluation of the Donor Kidney; Evaluation of Transplant Nephrectomy; History of Kidney Transplantation; Hyperacute Rejection; Indications and Evaluation of Explant; Pathologic Classification of Cardiac Allograft Diseases; Pathologic Classification of Intestinal Allograft Diseases; Pathologic Classification of Lung Allograft Diseases; Pathologic Classification of Pancreas Allograft Diseases; Pathologic Classification of Renal Allograft Diseases; Polyomavirus Nephropathy; Protocol Biopsies; Reperfusion Injury; Site of Previous Biopsy |
Caldesmon |
actin interacting and calmodulin binding protein found in smooth muscle and other cell types |
|
Post-Transplant Lymphoproliferative Disorder |
Calretinin |
29 kDa calcium binding protein that is expressed in central and peripheral nervous system and in many normal and pathological tissues |
DAK-CALRET, 5A5, CAL 3F5, DC8, AB149 |
Evaluation of Failed Native and Transplanted Heart; Site of Previous Biopsy |
CD1a |
T-cell surface glycoprotein |
JPM30, CD1A, O10, NA1/34 |
Other Causes of End-Stage Lung Disease |
CD2 |
T-cell surface antigen, LFA2 |
271, MT910, AB75, LFA-2 |
Epstein-Barr Virus, Intestine; NK Cells |
CD3 |
T-cell receptor |
F7238, A0452, CD3-P, CD3-M, SP7, PS1 |
Acute Cellular Rejection, Pancreas; Acute Rejection; Chronic Antibody-Mediated Rejection; Chronic (Ductopenic) Rejection; Chronic T-Cell-Mediated Rejection; Clinical Considerations in Pancreas Transplant Evaluation; Engraftment Syndrome; Epstein-Barr Virus, Intestine; Epstein-Barr Virus, Liver; Evaluation of Failed Native and Transplanted Heart; Evaluation of Transplant Nephrectomy; History of Immunosuppression Drugs in Transplantation; Laboratory-Based Immune Monitoring in Organ Transplantation; Myocarditis; Post-Transplant Lymphoproliferative Disorder; Quilty Lesions; Recurrent Diabetes Mellitus |
CD4 |
T-cell surface glycoprotein, L3T4 |
IF6, 1290, 4B12, 1F6, CD04 |
Acute Rejection; Epstein-Barr Virus, Intestine; Laboratory-Based Immune Monitoring in Organ Transplantation; NK Cells; Post-Transplant Lymphoproliferative Disorder; Regulatory Immune Cells and Transplant Tolerance |
CD5 |
T-cell surface glycoprotein, Leu1, T1 |
NCL-CD5, 4C7, 54/B4, 54/F6 |
Epstein-Barr Virus, Intestine |
CD7 |
T-cell antigen precursor, Leu 9 |
272, CD7-272 |
Epstein-Barr Virus, Intestine |
CD8 |
T-cell coreceptor antigen, Leu 2, T-cytotoxic cells |
M7103, C8/144, C8/144B |
Acute Rejection; Epstein-Barr Virus, Intestine; Immune Response in
Organ Transplantation; Laboratory-Based Immune Monitoring In Organ Transplantation; Myocarditis; Post-Transplant Lymphoproliferative Disorder; Recurrent Diabetes Mellitus; Regulatory Immune Cells and Transplant Tolerance |
CD10 |
neutral endopeptidase |
NCL-270, CALLA, neprilysin, neutral endopeptidase, NEP |
Epstein-Barr Virus, Liver; Indications and Evaluation of Explant |
CD14 |
coreceptor for lipopolysaccharide binding protein |
FMC32 |
Acute Cellular Rejection, Intestine |
CD15 |
reacts with Reed-Sternberg cells of Hodgkin disease and with granulocytes |
VIM-2,3C4, LEU-M1, TU9, VIM-D5, MY1, CBD1, MMA, 3CD1, C3D1, Lewis x, SSEA-1 |
Post-Transplant Lymphoproliferative Disorder |
CD16 |
Fc receptor of IgG |
|
Chronic Antibody-Mediated Rejection; Immune Response in Organ Transplantation; NK Cells |
CD19 |
B-cell antigen |
|
Acute Rejection |
CD20 |
membrane spanning 4 domains of B-lymphocytes |
FB1, B1, L26, MS4A1 |
Acute Rejection; Chronic Rejection; Epstein-Barr Virus, Intestine; Epstein-Barr Virus, Liver; Mechanism of Action of Immunosuppressive Drugs; Post-Transplant Lymphoproliferative Disorder; Quilty Lesions; Regulatory Immune Cells and Transplant Tolerance |
CD21 |
CR2, complement component receptor 2, Epstein-Barr virus receptor |
IF8 |
Acute Cellular Rejection, Grade B; Acute Cellular Rejection, Heart; Pathologic Classification of Lung Allograft Diseases; Pathologic Classification of Rejection; Quilty Lesions; Site of Previous Biopsy |
CD25 |
If-2 receptor alpha |
2A3, 4C9 |
History of Kidney Transplantation; Regulatory Immune Cells and Transplant Tolerance; Transplantation and HLA |
CD30 |
tumor necrosis factor SF8 |
BER-H2, KI-1, TNFRSF8 |
Post-Transplant Lymphoproliferative Disorder |
CD31 |
platelet endothelial cell adhesion molecule |
JC/70, JC/70A, PECAM-1 |
Site of Previous Biopsy |
CD34 |
hematopoietic progenitor cell antigen |
MY10, IOM34, QBEND10, 8G12, 1309, HPCA-1, NU-4A1, TUK4, clone 581, BI-3c5 |
Chronic Antibody-Mediated Rejection; Engraftment Syndrome; Site of Previous Biopsy |
CD44 |
cell adhesion receptor for hyaluronic acid |
HCAM, CD44H, B-F24, A3D8, 2C5, CD44S, F10-44.2, 156-3C11, DF1485, BBA10, VFF-14, CD44V10, CD44V3, 3G5, CD44V3-10-P, CD44V3-10, 3D2, CD44V4_5, CD44V5, VFF-8, VFF-7, 2F10, VFF-18, CD44V6, CD44V7, VFF-9, CD44V7_8, VFF-17 |
NK Cells |
CD45 |
leukocyte common antigen |
LCA, PD7/26, 1.22/4.14, T29/33, RP2/18, PD7, 2D1, 2B11+PD7/26 |
NK Cells |
CD49e |
integrein α-5; CD49 antigen-like family member E antibody |
Integrin-A2, Integrin-AV |
NK Cells |
CD56 |
NCAM (neutral cellular adhesion molecule) |
MAB735, ERIC-1, 25-KD11, 123C3, 24-MB2, BC56C04, 1B6, 14-MAB735, NCC-LU-243, MOC-1 |
NK Cells |
CD57 |
β-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) |
LEU-7, NK1, HNK-1, TB01, B3GAT1 |
NK Cells |
CD61 |
cluster of differentiation found on thrombocytes corresponding to glycoprotein IIb/IIIa |
Integrin, beta 3 (platelet glycoprotein IIIa), ITGB3, GP3A, GPIIIa, Y2/5, HPA |
Calcineurin Inhibitor Toxicity; Hyperacute Rejection; mTOR Inhibitor Toxicity; Renal Artery or Vein Thrombosis |
CD62 |
cell adhesion molecule found on leukocytes that acts as a homing receptor |
L-selectin, lymphocyte adhesion molecule 1, LAM-1, LAM1, LECAM1, LEU 8 |
Calcineurin Inhibitor Toxicity |
CD62L |
cell adhesion molecule found on leukocytes that acts as a homing receptor |
9H6, lymphocyte adhesion molecule 1, Leu-8, L-selectin |
Calcineurin Inhibitor Toxicity; NK Cells |
CD68 |
cytoplasmic granule protein of monocytes, macrophages |
PG-M1, KP-1 |
Acute Cellular Rejection, Pancreas; Acute Rejection; Anti-GBM Disease In Alport Syndrome; Chronic Antibody-Mediated Rejection; Clinical Considerations in Pancreas Transplant Evaluation; Engraftment Syndrome; Evaluation of Failed Native and Transplanted Heart; Malakoplakia; Other Causes of End-Stage Lung Disease; Post-Transplant Lymphoproliferative Disorder; Regulatory Immune Cells and Transplant Tolerance |
CD79-a |
immunoglobulin-associated alpha, MB1 |
MB-1, 11D10, 11E3, CD79A, HM47/A9, HM57, JCB117, CD79a |
Epstein-Barr Virus, Intestine; Post-Transplant Lymphoproliferative Disorder |
CD94 |
natural killer (NK) cell antigen that is also expressed on activated CD8(+) T cells |
|
NK Cells |
CD138 |
syndecan; a useful marker for plasma cells |
B-B4, AM411-10M, MI15 |
Acute Cellular Rejection, Intestine; Epstein-Barr Virus, Liver |
CD163 |
macrophage hemoglobin scavenging system |
10D6 |
Malakoplakia |
CK-PAN |
cytokeratin-pan (AE1/AE3/LP34); cocktail of high- and low-molecular weight cytokeratins |
keratin pan, MAK-6, K576, LU-5, KL-1, KC-8, MNF 116, pankeratin, pancytokeratin |
mTOR Inhibitor Toxicity |
CK7 |
cytokeratin 7, low-molecular weight cytokeratin |
K72.7, KS7.18, OVTL 12/30, LDS-68, CK 07 |
Epstein-Barr Virus, Intestine |
CK19 |
cytokeratin 19, low-molecular weight cytokeratin |
BA17, RCK108, LP2K, B170, A53-BA2, KS19.1, 170.2.14 |
Chronic (Ductopenic) Rejection |
CMV |
cytomegalovirus |
|
Acute Cellular Rejection, Pancreas; Acute Rejection; Adenovirus, Kidney; Adenovirus, Liver; Antibody-Mediated Rejection, Pancreas; Bacterial and Fungal Infections; Colon Rejection; Cytomegalovirus; Cytomegalovirus Nephritis; Epstein-Barr Virus, Liver; Intraabdominal and Opportunistic Infections; Laboratory-Based Immune Monitoring in Organ Transplantation; Rotavirus, Cytomegalovirus, and Herpes Simplex Virus; Viral Infections |
Collagen III |
CIV22, COL4A [1-5], collagen α-1(IV) chain |
COL3A1, Collagen alpha 1(III) chain, Collagen III alpha 1 chain precursor, Collagen III alpha 1 polypeptide, Collagen type III alpha 1 (Ehlers Danlos syndrome type IV autosomal dominant), Collagen type III alpha 1, Collagen type III alpha, EDS4A, Ehlers Danlos syndrome type IV, autosomal dominant; Fetal collagen, Type III collagen |
Evaluation of Fibrosis in Renal Allograft |
Collagen IV |
major constituent of the basement membranes along with laminins, proteoglycans, and enactins |
CIV22, COL4A [1-5], collagen α-1(IV) chain |
Hyperperfusion Injury |
Cytokeratin |
|
|
mTOR Inhibitor Toxicity; Recurrent Primary Biliary Cirrhosis; Site of Previous Biopsy |
Cytokeratin 5/6 |
high-molecular weight cytokeratins |
D5/16 B4 |
Site of Previous Biopsy |
Cytokeratin 7 |
low-molecular weight cytokeratin |
K72.7, KS7.18, OVTL 12/30, LDS-68, CK 07, CK7 |
Recurrent Primary Biliary Cirrhosis |
Desmin |
class III intermediate filaments found in muscle cells |
M760, DE-R-11, D33, DE5, DE-U-10, ZC18 |
Epstein-Barr Virus, Intestine; Other Causes of End-Stage Lung Disease; Post-Transplant Lymphoproliferative Disorder |
Desmoplakin |
major high molecular weight protein of desmosomes |
250/210 kDa paraneoplastic pemphigus antigen antibody, DPI DPII, DP, DPII, KPPS2, PPKS2 |
Arrhythmogenic Right Ventricular Cardiomyopathy |
EBER |
Epstein-Barr virus encoded RNA |
|
Acute Cellular Rejection, Intestine; Acute Rejection; Colon Rejection; Epstein-Barr Virus, Intestine; Epstein-Barr Virus, Liver; Indications and Evaluation of Explant; Pathologic Classification of Intestinal Allograft Diseases; Post-Transplant Lymphoproliferative Disorder; Stomach Rejection |
EBV-LMP |
Epstein-Barr virus latent membrane protein |
LMP1, CS 1-4 |
Acute Rejection; Cytomegalovirus Nephritis; Epstein-Barr Virus, Intestine; Post-Transplant Lymphoproliferative Disorder |
Fibrinogen |
soluble plasma glycoprotein made by the liver and involved in blood coagulation |
|
Acute Cellular Rejection, Kidney; Calcineurin Inhibitor Toxicity |
FOXP3 |
forkhead box transcription factor P3 |
FoxP3, scurfin, JM2, Treg, 150D/E4, AIID, DIETER, MCG141961, MCG141963, PIDX, XPID |
Regulatory Immune Cells and Transplant Tolerance |
Glucagon |
hormone secreted by the pancreas; functions to increase blood glucose levels |
|
Chronic Allograft Rejection/Graft Sclerosis; Clinical Considerations in Pancreas Transplant Evaluation; Islet Cell Toxicity; Recurrent Diabetes Mellitus |
Granzyme B |
neutral serine protease |
GZM-B, 11F1, GR-B7 |
Recurrent Diabetes Mellitus |
HBcAg |
hepatitis B core antigen |
HBCAG |
Recurrent Hepatitis B Virus |
HBsAg |
hepatitis B surface antigen |
3E7, HBSAG |
Recurrent Hepatitis B Virus |
HLA-DR |
human leukocyte antigen DR |
DK22, LN3, TAL.1B5, LK8D3 |
Acute Rejection; Human Leukocyte Antigen System; Transplantation and HLA |
HSV1 |
herpes simplex virus 1 |
|
Herpes Simplex Virus; Viral Infections |
HSV1/2 |
herpes simplex virus 1 and 2 |
|
Cytomegalovirus Nephritis; Herpes Simplex Virus; Viral Infections |
HSV2 |
herpes simplex virus 2 |
|
Herpes Simplex Virus |
IgA |
immunoglobulin A |
|
ABO Blood Group Antigens and Transplantation; Acute Pyelonephritis; Coccidioidomycosis; Diseases That Recur In Allografts; Evaluation of the Donor Kidney; Evaluation of the End-Stage Kidney; Evaluation of Transplant Nephrectomy; Laboratory-Based Immune Monitoring in Organ Transplantation; Pathologic Classification of Renal Allograft Diseases; Protocol Biopsies |
IgG |
immunoglobulin B |
|
ABO Blood Group Antigens and Transplantation; Acute Antibody-Mediated Rejection, Intestine; Acute Pyelonephritis; Anti-GBM Disease In Alport Syndrome; Apheresis and Transplantation; Chronic Antibody-Mediated Rejection; Cytomegalovirus Nephritis; De Novo Membranous Glomerulonephritis; Diseases That Recur in Allografts; Evaluation of Transplant Nephrectomy; Hepatitis E Virus; Human Leukocyte Antigen System; Hyperacute Rejection; Laboratory-Based Immune Monitoring in Organ Transplantation; Pathologic Classification of Intestinal Allograft Diseases; Polyomavirus Nephropathy; Protocol Biopsies |
IgM |
immunoglobulin M |
|
ABO Blood Group Antigens and Transplantation; Apheresis and Transplantation; Calcineurin Inhibitor Toxicity; Cytomegalovirus Nephritis; De Novo Focal Segmental Glomerulosclerosis; De Novo Membranous Glomerulonephritis; Evaluation of the End-Stage Kidney; Hepatitis E Virus; Hyperacute Rejection; Intraabdominal and Opportunistic Infections; Laboratory-Based Immune Monitoring In Organ Transplantation |
Insulin |
|
HB125 |
Chronic Allograft Rejection/Graft Sclerosis; Clinical Considerations in Pancreas Transplant Evaluation; Islet Cell Toxicity; Recurrent Diabetes Mellitus |
JC virus |
|
|
Polyomavirus Nephropathy |
Kappa light chain |
|
KAPPA, κ light chain |
Anti-GBM Disease in Alport Syndrome; De Novo Membranous Glomerulonephritis; Diseases That Recur In Allografts; Epstein-Barr Virus, Liver; Evaluation of Fibrosis in Renal Allograft; Evaluation of Transplant Nephrectomy; Mechanism of Action of Immunosuppressive Drugs; Post-Transplant Lymphoproliferative Disorder; De Novo Membranous Glomerulonephritis; Diseases That Recur in Allografts; Epstein-Barr Virus, Liver; Evaluation of Transplant Nephrectomy; Mechanism of Action of Immunosuppressive Drugs |
Ki-67 |
Ki-67 (MIB-1); marker of cell proliferation |
MMI, KI88, IVAK-2, MIB1 |
Acute Allograft Ischemia; Engraftment Syndrome; Post-Transplant Lymphoproliferative Disorder |
Lambda light chain |
|
λ light chain, LAMBDA |
Anti-GBM Disease in Alport Syndrome; De Novo Membranous Glomerulonephritis; Diseases That Recur in Allografts; Epstein-Barr Virus, Liver; Post-Transplant Lymphoproliferative Disorder |
MOC-31 |
lung cancer marker |
|
Indications and Evaluation of Explant |
MPO |
myeloperoxidase |
|
Engraftment Syndrome |
MUC1 |
epithelial membrane antigen |
LICR-LON-M8, BC3, DF3, VU3D1, MUSEII, RD-1, MA695, MA552, PS2P446, 115D8 |
Accommodation |
Myeloperixidase |
|
MPO |
Diseases That Recur in Allografts |
Myogenin |
|
F5D, MYF3, MYF4, MYOGENIN, LO26 |
Epstein-Barr Virus, Intestine |
Myoglobin |
iron- and oxygen-building protein found in muscle tissue |
MG-1 |
Acute Allograft Ischemia; Evaluation of the Donor Kidney; mTOR Inhibitor Toxicity |
NCAM |
neutral cellular adhesion molecule |
CD56, MAB735, ERIC-1, 25-KD11, 123C3, 24-MB2, BC56C04, 1B6, 14-MAB735, NCC-LU-243, MOC-1 |
NK Cells |
PCNA |
proliferating cell nuclear antigen |
19 A2, PC10 |
Acute Allograft Ischemia |
Polyomavirus large T antigen |
|
|
Evaluation of Transplant Nephrectomy; Polyomavirus Nephropathy |
S100 |
Low molecular weight protein normally present in cells derived from neural crest (Schwann cells, melanocytes, and glial cells), chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes |
S-100, A6, 15E2E2, Z311, 4C4.9, S100 protein |
Other Causes of End-Stage Lung Disease |
Somatostatin |
|
|
Clinical Considerations in Pancreas Transplant Evaluation |
Surfactant |
phospholipoprotein formed by type II alveolar cells |
|
Other Causes of End-Stage Lung Disease |
Surfactant B |
|
18 kDa pulmonary sufractant protein, 6 kDa protein antibody, pulmonary surfactant-associated proteolipid SPL Phe, SFTB3, SFTPB, SP B, SPB |
Other Causes of End-Stage Lung Disease |
Surfactant C |
|
proSP-c, SFTPC |
Other Causes of End-Stage Lung Disease |
SV40 |
simian virus 40 |
|
Adenovirus, Kidney; Anti-GBM Disease in Alport Syndrome; Cytomegalovirus Nephritis; Evaluation of Transplant Nephrectomy; Polyomavirus Nephropathy |
Toxoplasma gondii |
Parasitic protozoan, causative organism of toxoplasmosis |
|
Microsporidiosis |
WT1 |
Wilms tumor gene 1 |
6F-H2, C-19 |
Evaluation of Failed Native and Transplanted Heart; mTOR Inhibitor Toxicity |
